Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Transcription profiling of human breast cancer biopsies taken before and after patients were treated with aromatase inhibitors

ABSTRACT: Molecular response to Aromatase Inhibitor Treatment in Primary Breast Cancer

ORGANISM(S): Homo sapiens

SUBMITTER: Anita Grigoriadis

PROVIDER: E-TABM-180 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Publications

Molecular response to aromatase inhibitor treatment in primary breast cancer.

Mackay Alan A Urruticoechea Ander A Dixon J Michael JM Dexter Tim T Fenwick Kerry K Ashworth Alan A Drury Suzanne S Larionov Alexey A Young Oliver O White Sharon S Miller William R WR Evans Dean B DB Dowsett Mitch M

Breast cancer research : BCR 20070101 3

<h4>Background</h4>Aromatase inhibitors such as anastrozole and letrozole are highly effective suppressants of estrogen synthesis in postmenopausal women and are the most effective endocrine treatments for hormone receptor positive breast cancer in such women. Little is known of the molecular effects of these agents on human breast carcinomas in vivo.<h4>Methods</h4>We randomly assigned primary estrogen receptor positive breast cancer patients to treatment with anastrozole or letrozole for 2 wee ...[more]

PMID: 17555561

Similar Datasets

Project description:In this study we performed a systematic evaluation of functional miRNA-mRNA interactions associated with the aggressiveness of breast cancer cells using a combination of integrated miRNA and mRNA expression profiling, bioinformatics prediction, and functional assays. Analysis of the miRNA expression identified 11 miRNAs that were differentially expressed, including 7 down-regulated (miR-200c, miR-205, miR-203, miR-141, miR-34a, miR-183, and miR-375) and 4 up-regulated miRNAs (miR-146a, miR-138, miR-125b1 and miR-100), in aggressive cell lines when compared to normal and less aggressive cell lines. Transient overexpression of miR-200c, miR-205, and miR-375 in MDA-MB-231 cells led to the inhibition of cell migration and invasion. The integrated analysis of miRNA and mRNA expression identified 35 known and novel target genes of miR-200c, miR-205, and mir-375, including CFL2, LAMC1, TIMP2, ZEB1, CDH11, PRKCA, PTPRJ, PTPRM, LDHB, and SEC23A. Surprisingly, the majority of these genes (27 genes) were target genes of miR-200c, suggesting that it plays a more important role in regulating the aggressiveness of breast cancer cells. We characterized one of the target genes of miR-200c, CFL2, and demonstrated that CFL2 is overexpressed in aggressive breast cancer cell lines and can be significantly down-regulated by exogenous miR-200c. Tissue microarray analysis further revealed that CFL2 expression in primary breast cancer tissue correlated with tumor grade. To our knowledge, this study is the first systematic screening of functional miRNA target genes in aggressive breast cancer cells. The results obtained from this study may improve our understanding of the role of these candidate miRNAs and their target genes in relation to breast cancer aggressiveness and ultimately lead to the identification of novel biomarkers associated with prognosis. Affymetrix Gene 1.0 ST arrays were performed according to the manufacturer's directions on RNA extracted from breast cancer cell lines which are treated with miRNA mimic

Dataset Information

Transcription profiling of human breast cancer biopsies taken before and after patients were treated with aromatase inhibitors

Publications

Molecular response to aromatase inhibitor treatment in primary breast cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure